Corrigendum: Association of CTLA-4 gene variants with response to therapy and long-term survival in metastatic melanoma patients treated with ipilimumab: An Italian melanoma intergroup study [Front Immunol, 8, (2017), (386)] doi: 10.3389/fimmu.2017.00386

on behalf of the Italian Melanoma Intergroup (IMI)

Research output: Contribution to journalComment/debate


A corrigendum on Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study by Queirolo P, Dozin B, Morabito A, Banelli B, Piccioli P, Fava C, et al. Front Immunol (2017) 8:386. doi: 10.3389/fimmu.2017.00386. In the original article, affiliation number 9 was wrong. The correct affiliation 9 is "Istituto Dermopatico dell'Immacolata IDI-IRCCS, Rome, Italy". This error does not change the scientific conclusions of the article in any way. The original article has been updated. Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Original languageEnglish
Article number403
JournalFrontiers in Immunology
Issue numberMAR
Publication statusPublished - Mar 2 2018



  • Best overall response
  • CTLA-4 variants
  • Ipilimumab
  • Melanoma
  • Overall survival
  • Predictive/prognostic factor

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this